



Supplemental figure 1
TID PTH treatment increases trabecular bone volume without cortical changes.

A-F) Micro-CT analysis of trabecular bone from the tibiae of VEH and PTH treated mice; G,H) Representative micro-CT images of trabecular bone from the proximal tibiae of VEH or PTH treated mice; I) Micro-CT analysis of cortical bone from femurs and tibiae of VEH and PTH treated mice

* p<0.05, ** p<0.01, *** p<0.001. n= 5-6 per treatment group





Supplemental figure 2: Osteoblastic N-Cadherin is not required for PTH mediated expansion of HSCs. Percent of CD11b+ (left panels), B220+ (middle panels), and CD3+ (right panels) peripheral blood cells derived from engrafted donor cells. Donor type indicated on the x-axis. Analysis was performed at 8, 12 and 16 weeks. Each dot represents an individual recipient mouse.

SUPPLEMENTAL TABLE 1

Antibody	Conjugated to	Clone	Supplier
B220 (CD45R)	Biotin	RA3-6B2	eBiosciences
Gr1 (Ly6G)	Biotin	RB6-8C5	eBiosciences
CD3e	Biotin	145-2C11	eBiosciences
Ter119	Biotin	TER119	eBiosciences
c-kit (CD117)	PE-Cy5	2B8	eBiosciences
Sca-1 (Ly6a/e)	PerCP-Cy5.5	D7	eBiosciences
FIt3	PE	A2F10	eBiosciences
Thy1.1 (CD90.1)	PE-Cy7	HIS51	eBiosciences
CD150	APC	9D1	eBiosciences
CD48	FITC	HM48-1	BioLegend
Streptavidin	PE-Texas Red		BD Biosciences
CD11b	APC-Alexa780	M1/70	eBiosciences
B220 (CD45R)	APC	RA3-6B2	eBiosciences
CD3	PerCP-Cy5.5	145-2C11	eBiosciences
CD45.1	PE	A20	BD Biosciences
CD45.2	FITC	104	BD Biosciences